ATTO insider trading
NasdaqGM HealthcareAttovia Therapeutics, Inc.: insider trade history from SEC Form 4 filings.
About Attovia Therapeutics, Inc.
Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments. The company's products include ATTO-1310, a novel ATTOBODY-based Fc-fusion protein therapeutic that inhibits IL-31; developed for the treatment of chronic pruritic diseases such as CPUO, high-itch AD, cholestatic pruritus, and CKD-aP; ATTO-2306, an ATTOBODY-based, half-life-extended immunoglobulin G (IgG)-fusion protein therapeutic that inhibits IL-13 and IL-31; developed for the treatment of AD and other immune-mediated skin diseases, such as CSU and PN; and ATTO-1091, a trispecific ATTOBODY-based Fc-fusion protein therapeutic that inhibits TL1A, IL-23, and integrin a4ß7; developed for IBD a chronic immune-mediated condition characterized by persistent inflammation of the gastrointestinal tract, includes ulcerative colitis (UC) and crohn's disease (CD). The company was incorporated in 2022 and is based in San Carlos, California.
Company website: www.attovia.com
ATTO insider activity at a glance
FilingIQ tracks 123 insider transactions for ATTO in filings since Aug 6, 2026. The most recent transaction is dated Aug 6, 2026.
Across the full history, 13 open-market purchases
and 92 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
How FilingIQ classifies each line, and the seven facts it shows on every open-market purchase and sale, are documented on the methodology page.
Latest ATTO Form 4 filings
Most recent disclosures. Sign up to filter by transaction code, insider role or dollar value.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for ATTO?
- FilingIQ tracks 123 Form 4 insider transactions for ATTO (Attovia Therapeutics, Inc.), covering filings from Aug 6, 2026 onwards. 123 of those are dated within the last 90 days.
- Are ATTO insiders net buyers or net sellers?
- Across the full Form 4 history for ATTO, 13 transactions (11%) were open-market purchases and 92 (75%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does ATTO insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ links every filing to the insider's SEC CIK, marks plan trades, tax withholding, option exercises, gifts, derivatives and amendments, and shows each open-market purchase and sale with the same fixed facts. It does not rate the stock.
- What sector is ATTO in?
- Attovia Therapeutics, Inc. (ATTO) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.04B.
Methodology & sources
Every ATTO insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). How lines are classified and which facts FilingIQ adds is documented on the methodology page; the people behind it are on the team page. Not investment advice; see disclaimer.